Research programme: vancomycin nanoparticles - AlphaRx

Drug Profile

Research programme: vancomycin nanoparticles - AlphaRx

Alternative Names: Vancomycin nanoparticles; Vansolin

Latest Information Update: 23 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AlphaRx
  • Class Glycopeptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Nosocomial pneumonia; Sepsis

Most Recent Events

  • 18 Feb 2010 Preclinical development is ongoing
  • 27 May 2008 AlphaRx establishes CRADA with US Army for the development of antibacterial nanoparticles in severe intracellular bacterial infections
  • 12 Nov 2007 Preclinical data added to the pharmacokinetics and Bacterial Infections pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top